Skip to content

US · AURA · BIOTECHNOLOGY

Aura Biosciences, Inc. (AURA) intrinsic value and stock valuation

$6.87as of 2026-11-21 · Mkt cap 826.46M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Aura Biosciences, Inc. DCF and intrinsic value

InvestorsCraft values AURA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from AURA’s statements →

Aura Biosciences, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Boston, MA 02135 aurabiosciences.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$0.00
20192025
Net income
-$-106.19M
20192025
Free cash flow
-$-85.19M
20192025
Total equity
$136.9M+47.9% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-112.79M-$-96.12M-$-84.99M-$-60.3M-$-35.25M
Net income-$-106.19M-$-86.92M-$-76.41M-$-58.76M-$-35.25M
EPSd-$-1.76M-$-1.75M-$-1.93M-$-1.96M-$-1.21M
Operating cash flow-$-84.74M-$-79.81M-$-63.85M-$-54.6M-$-32.41M
Capital expenditure-$-450K-$-1.25M-$-710K-$-1.09M-$-2.12M
Free cash flow-$-85.19M-$-81.06M-$-64.56M-$-55.7M-$-34.53M
Total assets$169.4M$182.5M$255.1M$223.9M$160M
Total debt$17.4M$18.8M$19.6M$20.9M$970K
Net debt-$-42.14M-$-12.92M-$-21.51M-$-100.72M-$-148.09M
Total equity$136.9M$152M$225.9M$195.6M$152.3M
Cash and short-term investments$144.2M$151.1M$226.2M$188.8M$149.1M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$1.29M$0.00$0.00
Gross profit$0.00$0.00-$-1.29M$0.00$0.00
Research and development expenses$90.3M$73.3M$63.9M$42.2M$25.2M
Selling, general and administrative expenses$22.5M$22.8M$19.8M$18.1M$10.1M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$112.8M$96.1M$83.7M$60.3M$35.3M
Cost and expenses$112.8M$96.1M$85M$60.3M$35.3M
Interest income$6.63M$9.43M$8.59M$1.86M$10K
Interest expense$0.00$0.00$0.00$0.00$10K
Depreciation and amortization$1.13M$1.22M$1.29M$1.18M$830K
Ebitda-$-104.95M-$-85.58M-$-74.98M-$-57.59M-$-34.41M
Operating income-$-112.79M-$-96.12M-$-84.99M-$-60.3M-$-35.25M
Total other income/expenses, net$6.71M$9.31M$8.72M$1.53M-$0.00
Income before tax-$-106.08M-$-86.81M-$-76.27M-$-58.76M-$-35.25M
Income tax expense$110K$110K$140K$0.00$0.00
Net income-$-106.19M-$-86.92M-$-76.41M-$-58.76M-$-35.25M
Weighted average shares outstanding$60.3M$49.7M$39.6M$29.9M$29.2M
Weighted average diluted shares outstanding$60.3M$49.7M$39.6M$29.9M$29.2M
Balance sheet
20252024202320222021
Cash and short-term investments$144.2M$151.1M$226.2M$188.8M$149.1M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$149.7M$160.6M$231.8M$196.7M$153.7M
Property, plant and equipment, net$18.5M$20.6M$22M$26M$6.2M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$770K$0.00
Total non-current assets$19.7M$21.9M$23.3M$27.2M$6.33M
Total assets$169.4M$182.5M$255.1M$223.9M$160M
Accounts payable$1.55M$2.3M$1.79M$2.92M$2.4M
Short-term debt$3.24M$3.15M$2.69M$2.96M$610K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$18.4M$14.9M$12.4M$10.5M$7.36M
Long-term debt$14.1M$15.6M$16.9M$17.9M$360K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$14.1M$15.6M$16.9M$17.9M$360K
Capital lease obligations$3.24M$18.8M$19.6M$20.9M$970K
Total liabilities$32.5M$30.5M$29.2M$28.4M$7.71M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-480.42M-$-374.23M-$-287.31M-$-210.9M-$-152.14M
Accumulated other comprehensive income (loss)-$-100K$260K$540K-$-70K$0.00
Total equity$136.9M$152M$225.9M$195.6M$152.3M
Total investments$84.7M$119.4M$185.1M$68M$0.00
Total debt$17.4M$18.8M$19.6M$20.9M$970K
Net debt-$-42.14M-$-12.92M-$-21.51M-$-100.72M-$-148.09M
Cash flow statement
20252024202320222021
Net income-$-106.19M-$-86.92M-$-76.41M-$-58.76M-$-35.25M
Depreciation and amortization$1.13M$1.22M$1.29M$1.18M$830K
Stock-based compensation$14.3M$11.7M$8.77M$6.41M$2.31M
Change in working capital$5.97M-$-2.64M$4.44M-$-3.1M-$-320K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-850K$480K-$-1.04M$340K$1.05M
Net cash provided by operating activities-$-84.74M-$-79.81M-$-63.85M-$-54.6M-$-32.41M
Investments in property, plant and equipment-$-450K-$-1.25M-$-710K-$-1.09M-$-2.12M
Acquisitions, net$0.00$0.00$0.00$70K$0.00
Net cash used for investing activities$35.6M$68.8M-$-113.96M-$-67.87M-$-2.12M
Common stock issued$77.2M$1.59M$3.17M$8.55M$78.7M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$77.2M$1.59M$97.3M$95.6M$166.3M
Net change in cash$27.8M-$-9.39M-$-80.52M-$-26.84M$131.7M
Cash at end of period$60.3M$32.5M$41.9M$122.4M$149.2M
Operating cash flow-$-84.74M-$-79.81M-$-63.85M-$-54.6M-$-32.41M
Capital expenditure-$-450K-$-1.25M-$-710K-$-1.09M-$-2.12M
Free cash flow-$-85.19M-$-81.06M-$-64.56M-$-55.7M-$-34.53M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Aura Biosciences, Inc.

        Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.

        CEO
        Natalie C. Holles
        Employees
        113
        Beta
        0.40

        Explore

        Frequently asked questions

        What is the intrinsic value of Aura Biosciences, Inc. (AURA)?

        InvestorsCraft does not currently publish an intrinsic value for AURA. How the IC value is calculated.

        Is AURA undervalued?

        InvestorsCraft does not publish an undervaluation signal for AURA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.